Board of Directors, ClearPath Diagnostics (Realized), Brightview and The Women’s Health Group
Dr. Bob DeCresce currently serves on the Board of Directors of BrightView and The Women’s Health Group, Shore Capital's medication-assisted treatment and women’s health platform investments, respectively. Bob was also a member of the Board of Directors of ClearPath Diagnostics, a former Shore laboratory services portfolio company serving the women’s health industry. Bob has been Director of Clinical Laboratories at Rush University Medical Center since 1991 and serves as Chairman of the Department of Pathology at Rush Medical College in Chicago. In addition to serving on multiple lab company boards, Bob is a Director for VWR a worldwide distributor of scientific equipment and supplies with $4 billion in global sales.
From 1983 until 1987, Bob served as Vice President of MetPath, Inc., a division of Corning, Inc., and a predecessor to Quest Diagnostics. He was also previously on the Board of PathLab, Inc., a Madison Dearborn Portfolio Company sold to LabCorp in 2001 in a $110 million transaction.
Dr. DeCresce has a Bachelor of Science degree from Boston College, an MD from Columbia University College of Physicians and Surgeons and a Master of Public Health and an MBA from Columbia University.